A strategy of Day14 bone marrows and early intervention is not superior to a strategy of noDay14 bone marrows and delayed intervention in patients with acute myeloid leukemia.
Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bone Marrow
/ drug effects
Female
Follow-Up Studies
Humans
Induction Chemotherapy
/ mortality
Intention to Treat Analysis
Leukemia, Myeloid, Acute
/ drug therapy
Male
Middle Aged
Neoplasm Recurrence, Local
/ drug therapy
Neoplasm, Residual
/ drug therapy
Prognosis
Remission Induction
Retrospective Studies
Survival Rate
Young Adult
Acute myeloid leukemia
Day14 marrow
delayed reinduction
early reinduction
induction chemotherapy
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
pubmed:
3
5
2019
medline:
29
7
2020
entrez:
3
5
2019
Statut:
ppublish
Résumé
We conducted a retrospective study of 364 acute myeloid leukemia patients treated using a Day14 or a noDay14 strategy. Under the Day14 strategy, patients received an interim marrow at 7-10 days following chemotherapy and, in case of residual disease, received immediate reinduction chemotherapy. Under the noDay14 strategy patients were only evaluated at end-of-induction (EOI). Overall induction mortality was higher in the Day14 cohort (8.3 vs. 3.6%,
Identifiants
pubmed: 31043109
doi: 10.1080/10428194.2018.1543878
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM